Volume 18 Issue 10, October 2018

Volume 18 Issue 10

‘CAR T cell race’, inspired by the Review on p605

Cover design: Simon Bradbrook

Comment

Research Highlights

  • Research Highlight |

    Infant immune systems are highly diverse at birth but then show convergence in the first three months of life.

    • Yvonne Bordon
  • Research Highlight |

    Naive CD4+ T cells are prepared for rapid activation and metabolic remodelling through the derepression of a poised translational machinery, which occurs independently of nutrient-sensing pathways.

    • Kirsty Minton
  • Journal Club |

    Adrian Liston describes two papers by Nicole Le Douarin and colleagues from the 1980s that used a chick–quail graft system to show the existence of dominant T cell tolerance.

    • Adrian Liston

Reviews

  • Review Article |

    This Review explores the challenges and opportunities of taking CARs down new therapeutic roads, in terms of developing chimeric antigen receptors (CARs) for treating infectious disease, autoimmunity and transplant rejection.

    • Colby R. Maldini
    • , Gavin I. Ellis
    •  & James L. Riley
  • Review Article |

    Histone deacetylases (HDACs) and histone acetyltransferases mediate reversible acetylation of histones and many other non-histone proteins to regulate gene expression and protein function. Here, the authors describe the myriad activities of HDACs in CD4+ T cells and the potential use of HDAC inhibitors as therapeutics for immune-mediated diseases.

    • Wilfried Ellmeier
    •  & Christian Seiser
  • Review Article |

    CD4+ T cells provide help to CD8+ T cells via lymph node-resident dendritic cells. In this Review, the authors discuss the molecular nature of help signals and how they can be harnessed to improve cancer immunotherapy.

    • Jannie Borst
    • , Tomasz Ahrends
    • , Nikolina Bąbała
    • , Cornelis J. M. Melief
    •  & Wolfgang Kastenmüller
  • Review Article |

    IL-2 is well known for its crucial role in driving T cell responses. Now, with improved knowledge of its expression, signalling and regulation, the therapeutic potential of administering or inhibiting IL-2 is being explored to treat autoimmune diseases, infectious diseases and cancer.

    • Rosanne Spolski
    • , Peng Li
    •  & Warren J. Leonard